Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells.
BACKGROUND
Microtubules are considered major therapeutic targets in patients with breast cancer. In spite of their essential role in biological functions including cell motility, cell division and intracellular transport, microtubules have not yet been considered as critical actors influencing tumor cell aggressivity. To evaluate the impact of microtubule mass and dynamics on the phenotype and sensitivity of breast cancer cells, we have targeted tubulin binding cofactor C (TBCC), a crucial protein for the proper folding of alpha and beta tubulins into polymerization-competent tubulin heterodimers.


METHODS
We developed variants of human breast cancer cells with increased content of TBCC. Analysis of proliferation, cell cycle distribution and mitotic durations were assayed to investigate the influence of TBCC on the cell phenotype. In vivo growth of tumors was monitored in mice xenografted with breast cancer cells. The microtubule dynamics and the different fractions of tubulins were studied by time-lapse microscopy and lysate fractionation, respectively. In vitro sensitivity to antimicrotubule agents was studied by flow cytometry. In vivo chemosensitivity was assayed by treatment of mice implanted with tumor cells.


RESULTS
TBCC overexpression influenced tubulin fraction distribution, with higher content of nonpolymerizable tubulins and lower content of polymerizable dimers and microtubules. Microtubule dynamicity was reduced in cells overexpressing TBCC. Cell cycle distribution was altered in cells containing larger amounts of TBCC with higher percentage of cells in G2-M phase and lower percentage in S-phase, along with slower passage into mitosis. While increased content of TBCC had little effect on cell proliferation in vitro, we observed a significant delay in tumor growth with respect to controls when TBCC overexpressing cells were implanted as xenografts in vivo. TBCC overexpressing variants displayed enhanced sensitivity to antimicrotubule agents both in vitro and in xenografts.


CONCLUSIONS
These results underline the essential role of fine tuned regulation of tubulin content in tumor cells and the major impact of dysregulation of tubulin dimer content on tumor cell phenotype and response to chemotherapy. A better understanding of how the microtubule cytoskeleton is dysregulated in cancer cells would greatly contribute to a better understanding of tumor cell biology and characterisation of resistant phenotypes.
Hage-Sleiman
Rouba
R
Inserm U590, Laboratoire de Cytologie Analytique, Université Lyon 1, 69008 Lyon, France. rhs08@hotmail.com
Herveau
Stéphanie
S
Matera
Eva-Laure
EL
Laurier
Jean-Fabien
JF
Dumontet
Charles
C
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002453:Cell Cycle / Q000502:physiology; D048708:Cell Growth Processes / Q000187:drug effects / Q000502:physiology; D045744:Cell Line, Tumor; D003593:Cytoplasm / Q000378:metabolism; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D008826:Microbial Sensitivity Tests; D008870:Microtubules / Q000187:drug effects / Q000378:metabolism; D018832:Molecular Chaperones / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D017239:Paclitaxel / Q000494:pharmacology; D014162:Transfection; D014404:Tubulin / Q000378:metabolism; D050257:Tubulin Modulators / Q000494:pharmacology*; D014747:Vinblastine / Q000031:analogs & derivatives / Q000494:pharmacology; D000077235:Vinorelbine; D000093542:Gemcitabine
D018832:Molecular Chaperones; D014404:Tubulin; D050257:Tubulin Modulators; C455270:tubulin-specific chaperone C; D003841:Deoxycytidine; D014747:Vinblastine; D017239:Paclitaxel; D000077235:Vinorelbine; D000093542:Gemcitabine
J Cell Biol. 1990 Dec;111(6 Pt 2):3003-12
2269663
Iran Biomed J. 2007 Oct;11(4):209-14
18392081
Exp Cell Res. 2007 Feb 1;313(3):473-85
17188265
Biochem Soc Trans. 2005 Dec;33(Pt 6):1269-72
16246095
J Cell Biol. 1987 Feb;104(2):289-302
2879846
J Cell Biol. 1990 Sep;111(3):1039-45
2391359
Clin Cancer Res. 2005 Jan 1;11(1):298-305
15671559
Curr Cancer Drug Targets. 2007 Dec;7(8):697-703
18220530
Curr Biol. 2002 Sep 3;12(17):1519-23
12225668
Nat Rev Cancer. 2004 Apr;4(4):253-65
15057285
Biochemistry. 1993 Feb 9;32(5):1285-93
8448138
Breast Cancer Res Treat. 2004 Feb;83(3):249-89
14758095
Cancer Chemother Pharmacol. 2007 Jun;60(1):27-34
17021819
Genes Dev. 2002 Apr 15;16(8):959-71
11959844
J Biol Chem. 1999 Aug 20;274(34):24054-8
10446175
J Cell Sci. 1992 Jul;102 ( Pt 3):401-16
1506423
Curr Opin Cell Biol. 1998 Feb;10(1):123-30
9484604
Breast Cancer Res Treat. 1999 Jul;56(1):91-7
10517346
FEBS Lett. 2005 Jul 4;579(17):3515-24
15963512
Trends Cell Biol. 1997 Dec;7(12):479-84
17709011
Nature. 1995 May 18;375(6528):250-3
7746329
Apoptosis. 2003 Oct;8(5):413-50
12975575
Curr Cancer Drug Targets. 2007 Dec;7(8):730-42
18220533
J Struct Biol. 2001 Aug;135(2):219-29
11580271
PLoS One. 2009 Oct 15;4(10):e7478
19829707
Bioessays. 1998 Oct;20(10):830-6
9819570
Curr Cancer Drug Targets. 2003 Jun;3(3):193-203
12769688
Exp Cell Res. 2007 Feb 1;313(3):425-36
17184771
Mol Biol Cell. 2001 Apr;12(4):971-80
11294900
Curr Med Chem Anticancer Agents. 2002 Jan;2(1):1-17
12678749
Nat Rev Mol Cell Biol. 2003 Dec;4(12):938-47
14685172
FASEB J. 2008 Jan;22(1):168-82
17704193
Bull Cancer. 2005 Feb;92(2):E25-30
15749640
J Cell Biol. 1996 Oct;135(1):201-14
8858174
Cancer Res. 2003 Sep 15;63(18):6026-31
14522931
J Biol Chem. 1995 Oct 13;270(41):23910-3
7592580
Cancer Cell. 2006 Dec;10(6):515-27
17157791
Cancer Lett. 2004 Jul 8;210(1):7-15
15172115
J Biol Chem. 1991 Feb 5;266(4):2606-14
1899243
Cell Mol Life Sci. 2005 Dec;62(24):3039-56
16314924
J Cell Biol. 1988 Jan;106(1):141-9
3276710
Cancer Res. 1996 Feb 15;56(4):816-25
8631019
Biochim Biophys Acta. 2008 Apr;1785(2):96-132
18068131
J Cell Biol. 1997 Aug 25;138(4):821-32
9265649
Mol Biol Cell. 2006 May;17(5):2476-87
16525022
J Biol Chem. 2002 Apr 26;277(17):14629-34
11847227
Cell. 1996 Jul 26;86(2):287-96
8706133
Cancer Res. 2001 Jul 1;61(13):5024-7
11431336
Cancer Res. 1978 Nov;38(11 Pt 2):4327-39
212193